Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy

Szu-Jung Chen,Li-Hsien Chen,Yu-Min Yeh,Chou-Ching K Lin,Peng-Chan Lin,Han-Wei Huang,Meng-Ru Shen,Bo-Wen Lin,Jeng-Chang Lee,Cheng-Che Lee,Yueh-Feng Lee,Huai-Chueh Chiang,Jang-Yang Chang
DOI: https://doi.org/10.7150/thno.54793
IF: 11.6
2021-01-01
Theranostics
Abstract:<p><b>Rationale:</b> Oxaliplatin-induced peripheral neuropathy (OIPN) is a common adverse effect that causes delayed treatment and poor prognosis among colorectal cancer (CRC) patients. However, its mechanism remains elusive, and no effective treatment is available.</p><p><b>Methods:</b> We employed a prospective cohort study of adult patients with pathologically confirmed stage III CRC receiving adjuvant chemotherapy with an oxaliplatin-based regimen for investigating OIPN. To further validate the clinical manifestations and identify a potential therapeutic strategy, animal models, and <i>in vitro</i> studies on the mechanism of OIPN were applied.</p><p><b>Results:</b> Our work found that (1) consistent with clinical findings, OIPN was observed in animal models. Targeting the enzymatic activity of cathepsin S (CTSS) by pharmacological blockade and gene deficiency strategy alleviates the manifestations of OIPN. (2) Oxaliplatin treatment increases CTSS expression by enhancing cytosol translocation of interferon response factor 1 (IRF1), which then facilitates STIM-dependent store-operated Ca<sup>2+</sup> entry homeostasis. (3) The cytokine array demonstrated an increase in anti-inflammatory cytokines and suppression of proinflammatory cytokines in mice treated with RJW-58. (4) Mechanistically, inhibiting CTSS facilitated olfactory receptors transcription factor 1 release from P300/CBP binding, which enhanced binding to the interleukin-10 (IL-10) promoter region, driving IL-10 downstream signaling pathway. (5) Serum CTSS expression is increased in CRC patients with oxaliplatin-induced neurotoxicity.</p><p><b>Conclusions:</b> We highlighted the critical role of CTSS in OIPN, which provides a therapeutic strategy for the common adverse side effects of oxaliplatin.</p>
medicine, research & experimental
What problem does this paper attempt to address?